EcoDrugPlus

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSMPUG00000002256
Gene Symbol: CXCR4
2 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSMPUG00000007138
Gene Symbol: CFTR
2 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSMPUG00000006829
Gene Symbol: DNMT1
2 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSMPUG00000017701
Gene Symbol: TOP1
2 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSMPUG00000014680
Gene Symbol: TOP2A
2 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSMPUG00000012113
Gene Symbol: TOP2B
4 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSMPUG00000008864
Gene Symbol: EML4
2 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSMPUG00000016308
Gene Symbol: EPHA2
2 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSMPUG00000008263
Gene Symbol: EPHA3
2 Cross references
215 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSMPUG00000015832
Gene Symbol: EPHB4
2 Cross references
166 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSMPUG00000016009
Gene Symbol: F2RL3
2 Cross references
197 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSMPUG00000004405
Gene Symbol: FXYD2
1 Cross references
74 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).